Foundery, a biotechnology venture studio focused on transla6ng immunology discoveries into drug candidates, today announced an initial close of its inaugural fund, Foundery I, LP (“Foundery Fund I”), with total capital commitments and contributed assets as of the closing equal to $29.6 million. Founded in 2021 by science-first industry leaders Max Krummel, Ph.D., Michel Streuli, Ph.D., and Venkataraman “Sriram”, Ph.D., Foundery seeks to validate early-stage immunotherapy programs in collaboration with university researchers and their ins6tu6ons.
Max Krummel, Ph.D. is a member of the UCSF faculty and a leading voice in the area of immunological healthcare.